Enveric Biosciences (FRA:SLZ0) Stock Based Compensation: €0.62 Mil (TTM As of Mar. 2026)


FRA:SLZ0 Enveric Biosciences Inc FRA:SLZ0
30 GF Score
Price €56.07
! 1 Warning Sign
View Full Analysis

What is Enveric Biosciences Stock Based Compensation?

Enveric Biosciences FRA:SLZ0 30 Stock Based Compensation is €0.62 Mil as of Mar. 2026. GuruFocus rates FRA:SLZ0 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Enveric Biosciences's Stock Based Compensation for the three months ended in Mar. 2026 was €0.08 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €0.62 Mil.

Enveric Biosciences Stock Based Compensation Related Terms

Enveric Biosciences Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Enveric Biosciences's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enveric Biosciences Stock Based Compensation Chart

Enveric Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.15 2.47 1.97 1.49 0.71

Enveric Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.18 0.16 0.21 0.08
FRA:SLZ0
30GF Score
Enveric Biosciences Inc FRA:SLZ0
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enveric Biosciences Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.62 Mil.

What does a Stock Based Compensation of €0.62 Mil mean?
Enveric Biosciences (FRA:SLZ0) has a Stock Based Compensation of €0.62 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Enveric Biosciences and its competitors.
Is Enveric Biosciences' Stock Based Compensation too high?
Enveric Biosciences' current Stock Based Compensation is €0.62 Mil. Overall, Enveric Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Enveric Biosciences' Stock Based Compensation compare to APVO and CNSP?
Enveric Biosciences' Stock Based Compensation of €0.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Enveric Biosciences and its competitors. Enveric Biosciences's current Stock Based Compensation is €0.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enveric Biosciences stock overvalued right now?
Enveric Biosciences (FRA:SLZ0) has a current Stock Based Compensation of €0.62 Mil. The current Stock Based Compensation is €0.62 Mil. Enveric Biosciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Enveric Biosciences (FRA:SLZ0), the current Stock Based Compensation is €0.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enveric Biosciences Business Description

Other Exchanges ENVB:USA
Address 245 First Street, 18th Floor, Riverview II, Cambridge, MA, USA, 02142
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
30GF Score

Get the complete analysis for FRA:SLZ0

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.07
Price